Observation of Patients With Transfusional Hemosiderosis Treatment With Deferasirox
- Registration Number
- NCT01394029
- Lead Sponsor
- Novartis Pharmaceuticals
- Brief Summary
This study will observe patients with transfusional hemosiderosis treated with deferasirox in actual practice setting.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 120
Inclusion Criteria
-Patients treated with deferasirox for transfusional hemosiderosis according to the local prescribing information.
(the patients are either beginning treatment with deferasirox at the time of enrollment in the sentinel site monitoring or are currently under treatment with deferasirox and have started the treatment under prescription up to twelve months prior to enrollment in the sentinal site monitoring.
Read More
Exclusion Criteria
- Patients with non-transfusional hemosiderosis
- Patients treated with deferasirox in an interventional clinical trial
Other protocol-defined inclusion/exclusion criteria may apply.
Read More
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description deferasirox deferasirox -
- Primary Outcome Measures
Name Time Method Adverse Drug Reactions 3 years Observed over 3 years for each patient
Serum Creatinine and liver enzyme levels 3 years Observed over 3 years for each patient
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Novartis Investigative Site
🇬🇧London, United Kingdom